This site is intended for UK healthcare professionals only
chronic-conditions-logo
This webcast series and supporting materials was developed by the Chronic Conditions faculty in conjunction with OmniaMed Communications. The sponsoring companies have had no input into the agenda, speaker selection, presentations or collateral content, with the exception of the symposium sessions, for which the respective sponsoring companies are fully responsible.

Chronic Conditions Month 2023

Cardiovascular

Join us for a series of interactive webinars and podcasts to help you optimise care for people with chronic conditions

The agenda

13.00–13:45

Hot topics: Inherited, genetic and less common cardiac conditions

  • Red flags not to miss in primary care
  • Appropriate ECG risk stratification
  • Use of innovative technology

13.45-14.20

Reducing cardiovascular events in high-risk patients: A practical approach

This meeting contains promotional content and is organised and funded by Amarin Pharmaceuticals Ireland Limited.
For healthcare professionals located in Great Britain and Northern Ireland only

14:20- 15:00

Red flags and rare presentations

  • A series of case studies, exploring unusual symptoms and causes of ill health in people with cardiovascular disease

The speakers

Dr Yassir Javaid

GPwSI Cardiology, Northampton

Dr Javaid qualified from Cambridge University and completed his VTS training in Northampton. He has a specialist interest in cardiology and echocardiography and was a clinical lead in the Northamptonshire Community Cardiology service, which had a focus on patients with heart failure and valve disease. He was named Pulse “GP of the Year” in 2015 for his work in reducing stroke emergency admissions in the East Midlands. He is on the editorial board for the British Journal of Cardiology.

Professor Derek Connolly

Consultant Cardiologist and Director of Research and Development at Birmingham City Hospital

Professor Derek Connolly is a Consultant Cardiologist and the Director of Research and Development at Birmingham City Hospital and the Clinical lead for cardiac care for the local integrated Care System. He is an Honorary clinical associate Professor at Aston medical school and an Senior Clinical Lecturer at the Institute of Cardiovascular Sciences, University of Birmingham, UK.
He trained in Edinburgh, Cambridge, London and San Diego where he was a Carnegie Scholar. He has a first class degree in Pharmacology from the University of Edinburgh where he was the Brunton medallist and Keasbey Bursary holder. His BHF funded PhD in molecular cardiology is from the University of Cambridge. He is the Chief or Primary Investigator of multiple large trials in Cardiovascular medicine. He developed one of the UKs first primary angioplasty programmes, and one of the UKs largest cardiac CT programmes. He is a council member of the British Primary Care Cardiovascular Society.
He was on the design and naming team of the forthcoming super hospital, the Midland Metropolitan University Hospital which will open 2023.

Dr Waqas Tahir

GPwER Diabetes, Bradford

Dr Waqas Tahir is a GP partner in Affinity Care, a multi-site partnership covering 65,000 patients. He also works as a GPwER in Diabetes, advising and teaching local GPs and nurses. As Clinical lead for Diabetes, he has been leading the re-design of diabetes services, clinical guidelines, outcome measures and quality indicators across Bradford & Craven place with a focus on cardio-metabolic pathways.
He has a particular interest in translating evidence into practice, cardio-metabolic medicine, multi-morbidity and the role of technology and innovation in the delivery of patient care. He is a standing member of the NICE Indicator Advisory Committee as well as the clinical diabetes lead for West Yorkshire Health and Care Partnership. In the latter role, he has taken an avid interest in reducing health inequalities and championing diabetes awareness and prevention across the region. He has recently been appointed as the primary care clinical lead for diabetes clinical networks (Y&H) to support local health systems improve quality outcomes for their communities, reduce variation and drive improvement across the region.

Therapy webinar sponsor

Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our scientific research foundation to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly, committed to reducing cardiovascular risk and making a meaningful impact on patients’ lives.

©Amarin Pharmaceuticals Ireland Limited. AMARIN and VAZKEPA  (icosapent ethyl) are registered trademarks of Amarin Pharmaceuticals Ireland Limited in the United States, European Union, United Kingdom and other countries and regions.

For healthcare professionals only

Are you a healthcare professional?

The information is intended for healthcare professionals only.
Please confirm below.